OIOleg E. Ivlev

Oleg E. Ivlev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oleg E. Ivlev has a total of 260 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fortelyzin in the treatment of acute ischemic stroke due to basilar-artery occlusion: data from the observational study FORPI registry

    by N. A. Shamalov, M. Yu. Martynov, N. A. Marskaya, D. R. Khasanova, E. B. Yarovaya, I. A. Voznuk, L. V. Timchenko, A. M. Alasheev, N. V. Khalo, M. D. Bogatyreva, et al.

    The approach to reperfusion therapy for acute ischemic stroke (AIS) in cases of basilar artery occlusion (BAO) remains a matter of debate.    Objective:  to assess the safety and efficacy of Fortelyzin in patients with BAO in real-world clinical practice, based on data from the FORPI registry.   Material and methods.  The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in patients with ischaemic stroke. An analysis was conducted of the safety and efficacy of Fortelyzin in a group of patients with basilar artery occlusion who underwent intravenous thrombolytic therapy (IVT) and bridging therapy. The safety endpoint was the incidence of symptomatic intracranial haemorrhage (SICH) as defined by ECASS III and SITS-MOST, as well as all-cause mortality at 90 days. The efficacy endpoint was defined as good functional recovery, defined as a score of 0–2 on the modified Rankin Scale (MRS) at 90 days.    Results. This analysis included 1910 patients who underwent IVT and 53 patients who underwent bridging therapy. The median National Institutes of Health Stroke Scale (NIHSS) scores at admission were 9 and 12 points, respectively (p = 0.01). SICH incidence (ECASS III criteria) was significantly higher in the bridging therapy group compared to IVT group (6 % vs 1 %, p = 0.01). All-cause mortality at day 90 did not differ significantly between the groups (9 % and 7 %, respectively, p = 0.52). Good functional recovery at day 90 was achieved by 69 % of patients in the IVT group and 60 % of patients in the bridging therapy group (p = 0.31).    Conclusion. The use of Fortelyzin in AIS patients with BAO may be considered an effective and safe form of reperfusion therapy, as well as a component of bridging therapy aimed at increasing the number of favorable functional outcomes.

  • Open Access

    Fortelyzin in the treatment of minor acute ischemic stroke according to a subanalysis of the observational study FORPI registry

    by N. A. Shamalov, M. Yu. Martynov, N. A. Marskaya, D. R. Khasanova, E. B. Yarovaya, I. A. Voznuk, L. V. Timchenko, A. M. Alasheev, N. V. Khalo, M. D. Bogatyreva, et al.

    The question of whether intravenous thrombolytic therapy (ITT) is appropriate for patients with a minor stroke (NIHSS score < 5) remains a matter of debate. Fortelysin is a thrombolytic agent used to treat ischemic stroke.    Objective:  to assess the safety and efficacy of Fortelyzin in patients who have suffered a minor stroke in real-world clinical practice, based on data from a subanalysis of the FORPI registry.    Material and methods.  The FORPI registry is an open-label, prospective, non-interventional, observational study of Fortelyzin in patients with acute ischemic stroke. We analyzed the safety and efficacy of Fortelyzin in a group of patients with minor stroke characterized by an NIHSS < 5. Safety outcomes were the number of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality at day 90. The efficacy outcome was a functional independence, defined by modified Rankin scale (mRS) score of 0–2 points at day 90.    Results.  The analysis included 836 patients with an NIHSS < 5 points. The median age was 64 [56; 72] years, and the median NIHSS score at admission was 4 [3; 4] points. SICH according to ECASS III definition was observed in three patients of 836 (0.4 %), and according to SITS-MOST definition, in four patients of 836 (0.5 %). All-cause mortality at day 90 was 2.2 % (18/836). The proportion of patients with functional independence (mSR of 0–2 points) at day 90 reached in 88 % (737/836) of patients.    Conclusion. The FORPI registry provides compelling evidence that early intensive rehabilitation using Fortelyzin is characterised by a high level of safety and efficacy in patients who have suffered a minor stroke.

  • Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry

    by N.A. Shamalov, M.YU. Martynov, N.A. Marskaya, D.R. Khasanova, E.B. Yarovaya, I.A. Voznuk, L.V. Timchenko, A.M. Alasheev, N.V. Khalo, M D Bogatyreva, et al.

    Objective. The aim of this study was to evaluate the safety and efficacy of Fortelyzin in patients ≥80 years with ischemic stroke (IS) in real-world clinical practice using data from the FORPI registry. Material and Methods. Fortelyzin (INN/chemical name — a recombinant protein containing the amino acid sequence of staphylokinase, SuperGene LLC, Moscow, Russia) is a thrombolytic used for acute IS treatment within the first 4.5 hours of symptom onset. The FORPI registry is an open-label, prospective, non-interventional, observational study of Fortelyzin in patients with IS. We analyzed the safety and efficacy outcomes in patients ≥80 years compared with patients <80 years. Safety outcomes included the incidence of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by an mRS score of 0—2 on day 90. Results. 2649 (15%) patients were ≥80 years, and 14 987 (85%) patients were <80 years. The median age in the group of patients ≥80 years was 83 (82—86) years. Patients ≥80 years were characterized by a more complicated medical history and a higher median of NIHSS and mRS score. The sICH rate according to ECASS III definition in patients ≥80 years old was 4.0%, in patients <80 years old — 1.7% (OR 2.42 (1.90—3.07), p<0.001), according to SITS-MOST definition — 3.2% and 1.6%, respectively (OR 2.03 (1.56—2.61), p<0.001); in-hospital all-cause mortality was 17% and 7% (OR 2.76 (2.44—3.11, p<0.001), all-cause mortality on day 90 was 19% and 7% (OR 3.00 (2.67—3.37, p<0.001), respectively. Good functional recovery (mRS 0—2 score) on day 90 was achieved in 43% of patients ≥80 years and 64% in patients <80 years of age (OR 0.42 (0.38—0.46, p<0.001)). Conclusion. FORPI study showed that although the risk of sICH with Fortelyzin is higher in patients ≥80 years than in patients <80 years, it remains low, suggesting that thrombolytic therapy is safe and necessary in these patients.


  • Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry

    by N.A. Shamalov, M.YU. Martynov, E.I. Gusev, D.R. Khasanova, V.N. Nesterova, N.A. Marskaya, E.B. Yarovaya, Zh.YU. Chefranova, I.A. Voznuk, T.V. Kharitonova, et al.

    Objective. To evaluate the safety and efficacy of Fortelyzin during bridging therapy (thrombolysis followed by thrombectomy) in real-world clinical practice using data from the FORPI registry. Material and methods. The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in patients with acute ischemic stroke. In this article we analyzed the safety and efficacy of Fortelyzin in patients undergoing thrombolysis followed by thrombectomy. The safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by mRS score of 0—2 on day 90. Results. The analysis included 1116 patients undergoing thrombolysis followed by thrombectomy who were enrolled in a registry at 120 medical cites in 55 regions of the Russian Federation. The median patient age was 69 (61—77) years. The median NIHSS score at admission was 15 (12—19) points. The sICH rate according to ECASS III was 13% (144/1116), and according to SITS-MOST was 9% (98/1116). In hospital mortality rate was 27% (301/1116 patients). All-cause mortality on day 90 was 29% (322/1116 patients). Good functional outcome (mRS 0—2) on day 90 was achieved in 38% (422/1116) of patients. Conclusion. This study demonstrates the safety and efficacy of Fortelizin in bridging therapy of acute ischemic stroke in real-world clinical practice.


  • Open Access

    An algorithm for assessing cardiovascular risk in women 40 years and older based on digital mammogram analysis

    by A. G. Plisyuk, E. B. Yarovaya, G. O. Dolgushin, E. A. Mershina, D. D. Tsurskaya, E. M. Filichkina, O. E. Ivlev, V. E. Sinitsyn, Ya. A. Orlova

    Aim . To evaluate quantitative digital mammography parameters and develop an integrated cardiovascular risk (CVR) assessment system based on these parameters in women over 40 years of age. Material and methods . This retrospective study assessed mammograms from 1029 patients aged 40 to 75 years, for whom data were available to assess CVR. The mammographic parameters studied were breast density and calcifications. The data needed to assess the CVR were obtained from the medical records of patients receiving outpatient care. CVR was defined as low, moderate, high, and very high in accordance with the Russian Society of Cardiology guidelines. Results . Quantitative assessment of parameters obtained during preventive mammography allows us to divide patients into five groups with different probability of high and very high CVR. Using univariate logistic regression, odds ratios were calculated for each group compared to the reference value (D0). In groups D1, D2, D3, and D4, the odds of having stage 3-4 CVR were greater than 2,1, 3,5, 4,9, and 13,8 times, respectively. Similar or alternative algorithms for assessing CVR based on preventive mammography data have not been described in the literature. Conclusion . The development of a step-by-step cardiovascular risk assessment algorithm, potentially suitable for clinical practice, will significantly facilitate and accelerate identifying high cardiovascular risk in women over 40 years of age without the use of invasive diagnostic methods.


  • Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry

    by N.A. Shamalov, M.YU. Martynov, E.I. Gusev, N.A. Marskaya, D.R. Khasanova, E.B. Yarovaya, Z.YU. Chefranova, I.A. Voznuk, A.M. Alasheev, M.V. Sutormin, et al.

    Objective. To evaluate the safety and efficacy of Fortelyzin thrombolytic drug (non-immunogenic staphylokinase) in AIS patients in an «extended» therapeutic window from 4.5 to 24 h from symptoms’ onset based on data from the FORPI registry. Material and methods. Functional outcomes and the risk of intracranial hemorrhage after thrombolytic therapy (TLT) for acute ischemic stroke (AIS) are known to be directly dependent on the treatment time initiation. Although the most safe and effective time for TLT is the first 4.5 h from symptoms’ onset, a significant proportion of patients are hospitalized beyond this time window. The objective of this study is The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in AIS patients in real-world clinical practice. A comparative analysis of safety and efficacy outcomes was conducted in groups of patients who received TLT in the first 4.5 h after symptom onset and beyond 4.5 h time window. The safety endpoints were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST criteria, as well as all-cause mortality at day 90. The efficacy endpoint was good functional recovery, defined by a modified Rankin Scale (mRS) of 0—2 score at day 90. Results. The analysis included 17.636 patients with TLT performed in the first 4.5 h after symptom onset and 358 patients with TLT performed beyond 4.5 h time window (up to 24 hours). In the group of patients with TLT performed in the interval of 4.5—24 hours, there were statistically significantly fewer people over 80 years old (8% vs 16%, p=0.001), and a lower median age (66 vs 68 years, p=0.002) compared with the group of TLT within 4.5 hours. The NIHSS median was slightly higher in the group of patients with TLT performed beyond 4.5 h time window (11 (8—16) vs 11 (8—15), p=0.036). The incidence of sICH (ECASS III) within 4.5 h was 2% compared with 2.5% beyond 4.5 h time window (p=0.454). All-cause mortality at 90 days in the main population was 9%, which is comparable with the mortality rate in the 4.5—24 h group — 7% (p=0.160). Good functional recovery (mSR 0—2) at day 90 was achieved in 61% of patients in the group who received TLT within 4.5 h, compared with 65% of patients who received TLT beyond 4.5 h time window (p=0.227). Conclusion. FORPI registry demonstrates similar data on the safety and efficacy of TLT with Fortelyzin in AIS patients both within 4.5 hours and beyond 4.5 hours from symptoms’ onset.


  • Open Access

    The role of epidemiological research in the healthcare system using psychoemotional stress as an example: a multimedia training session for students majoring in Internal Medicine, Cardiology, and Healthcare Organization and Public Health

    by L. I. Gomanova, Yu. A. Balanova, S. A. Shalnova, O. E. Ivlev, V. A. Kutsenko, S. E. Evstifeeva, A. E. Imaeva, A. V. Kapustina, G. A. Muromtseva, S. Yu. Astanina, et al.

    Aim . To provide a methodological description and rationale for the de­veloped original training session "The Role of Epidemiological Research in the Healthcare System Using Psychoemotional Stress as an Example". Material and methods . This study used materials from a developed original training session on "The Role of Epidemiological Research in the Healthcare System Using Psychoemotional Stress as an Example" at the National Medical Research Center for Therapy and Preventive Medicine. This training session can be implemented using a multimedia presentation for residents, postgraduate students, and students enrolled in continuing professional education programs in Internal Medicine, Cardiology, and Healthcare Organization and Public Health; postgraduate medical students enrolled in Internal Medicine, Cardiology, and Healthcare Organization and Public Health; primary care physicians; directors and staff of public health and medical prevention centers; and directors and staff of healthcare authorities. Results . Key categories are identified, the lesson structure is defined, and the learning process management is demonstrated. Particular attention is paid to the implementation of the didactic principle "Connecting Theory with Practice". Conclusion. The training session integrates data from the largest Russian epidemiological studies (ESSE-RF and ESSE-RF2) into the specialist educational, a demonstration of their application at the descriptive statistics, work with Rosstat statistical data using information and analytical systems and the Internet, and the identification of key methodological features. It is aimed at improving the quality of training specialists in Internal Medicine, Cardiology, and Healthcare Organization and Public Health.

  • Open Access

    Association of Mammographic Markers of Cardiovascular Risk with Indicators of Systemic Inflammation in Women

    by G.O. Dolgushin, D.D. Tsurskaya, E.M. Filichkina, A.G. Plisyuk, E.A. Mershina, O.E. Ivlev, E.B. Yarovaya, V.E. Sinitsin, Ya.A. Orlova

    Aim. To evaluate the association between mammographic markers of cardiovascular risk (CVR) and systemic inflammation markers in women aged 40–75 years. Design. A cross-sectional study with retrospective data analysis. Materials and methods. Data from the medical records of 1069 female patients aged 40–75 years who underwent screening mammography at the outpatient clinic of Lomonosov Moscow State University were analyzed. Using a machine learning algorithm Uniform Manifold Approximation and Projection, they were divided into five groups (D0–D4) according to the SCORE cardiovascular risk scale: D4 — highest risk, D0 — lowest risk. The final analysis included data from 242 patients for whom results of a preventive examination, mammography, and complete blood count were available. They were divided by us into two groups only: those with higher (D3–D4, n = 89) and lower (D0–D2, n = 153) CVR. Complete blood count parameters were analyzed, and four inflammatory indices were calculated: neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-platelet ratio. Results. Women in the high-risk group (D3–D4) had significantly higher erythrocyte sedimentation rate (ESR) (p = 0.0003), absolute monocyte count in peripheral blood (p = 0.048), and neutrophil-to-platelet ratio (p = 0.047). To quantify the effect of these parameters, the odds ratio was calculated. ESR > 20 mm/h was associated with a 2.33-fold increase in the likelihood of high CVR, absolute monocyte count > 0.52 × 109/L with a 1.83-fold increase, and neutrophil-to-platelet ratio > 0.013 with a 1.95-fold increase. Conclusion. Elevated markers of systemic inflammation, such as monocyte count, ESR, and neutrophil-to-platelet ratio, are associated with a higher probability of detecting markers of high CVR on screening mammography. Further studies are needed to determine the causal nature of these associations and their pathogenetic mechanisms. Keywords: breast density, breast calcifications, cardiovascular risk, systemic inflammation, visceral obesity, erythrocyte sedimentation rate, monocytes, neutrophil-to-platelet ratio

  • Psychoemotional stress in the adult population of the Russian Federation perspective medical prevention directions

    by L.I. Gomanova, Yu.A. Balanova, S.A. Shalnova, O.E. Ivlev, V.A. Kutsenko, L.YU. Drozdova, E.S. Ivanova, A.V. Kontsevaya, O.M. Drapkina

    Psycho-emotional stress (PES) is a significant risk factor (RF) for the Russian population. It is necessary to search for scientific approaches to improve PES prevention, including patient routing in the current primary health care (PHC) system settings for the adult population. Objective. To review expert opinions and identify promising areas of medical prevention of psycho-emotional stress in the adult population of the Russian Federation within current primary health care settings. Materials and methods. The online questionnaire was conducted from April 16 to April 25, 2025, using the author’s questionnaire to assess the expert opinion of the Chief Consultants in medical prevention, heads of public health and medical prevention centers, and chief doctors of medical organizations of 37 constituent entities of the Russian Federation (n=133). Statistical analysis was performed using the R 4.2 environment. Results. The experts confirmed the importance of PES as an RF of chronic non-communicable diseases (CNCDs) and identified ways of routing the adult population with PES, including the integration of PES screening (questionnaire method) into the clinical examination, preventive counseling, and, if necessary, consultation with a medical psychologist/psychotherapist of medical organizations providing PHC for persons with high PES levels. The prospects of interaction between the departments (offices) of medical prevention, health centers, and offices of medical and psychological counseling are described. Low values of expert assessment regarding the full-time staffing of psychotherapists and/or medical psychologists of health centers (4.37±3.17 points), community awareness (5.84±2.43 points), and awareness of nursing staff and primary health care doctors (6.12±2.46 points) on the prevention, diagnosis, and treatment of PES as an RF for CNCD were revealed. Conclusion. The results of the study showed the importance of psycho-emotional stress as a risk factor for chronic non-communicable diseases and the need to identify and implement potential medical and organizational measures to prevent it in modern primary health care settings.


  • Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry

    by N A Shamalov, M Yu Martynov, E I Gusev, N A Marskaya, D R Khasanova, E B Yarovaya, Zh Yu Chefranova, I A Voznuk, A M Alasheev, S E Chuprina, et al.

    Objective. To evaluate safety and efficacy outcomes of Fortelyzin in AIS patients in the FORPI (Fortelyzin Population Investigation) registry. Material and methods. Between March 2021 and October 2024 AIS patients treated with Fortelyzin were enrolled in prospective, open, monitored, observational FORPI registry. Demographics, risk factors, baseline stroke severity, defined by National Institutes of Health Stroke Scale (NIHSS), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral haemorrhage (ICH) (according to the ECASS III and SITS-MOST criteria) within 36 h and all-cause mortality on day 90. Efficacy outcome was evaluated as a functional independence defined by modified Rankin scale (mRS score of 0—2) on day 90. Results. A total of 17 636 AIS patients were treated with Fortelyzin in 329 centres participated in the FORPI registry during the study period (median age 68 [60; 75]; 44% women; median baseline NIHSS score: 11 [8;16] points; median onset to treatment time: 2.4 [1.8; 3.1] h. 73% of patients (12947/17 636) received thrombolytic therapy in the first three hours from symptoms onset. The rate of symptomatic ICH according to the ECASS III criteria was 2% [1.8; 2.2] (356/17636), to the SITS-MOST criteria — 2% [1.8; 2.1] (330/17 636). All-cause mortality on day 90 was 9% [8.6; 9.4] (1588/17 636). The number of patients with mRS 0—2 score on day 90 was 61% [60.5; 61.9] (10799/17636). All safety and efficacy outcomes were comparable with FRIDA randomised clinical trial results. Conclusion. The presented data confirm that intravenous thrombolysis with Fortelyzin is safe and effective in routine clinical practice when used within 4.5 h of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy for suitable patients.